[go: up one dir, main page]

UA50721C2 - Композиція з подовженою дією, що містить цизаприд-(l)-тартрат - Google Patents

Композиція з подовженою дією, що містить цизаприд-(l)-тартрат

Info

Publication number
UA50721C2
UA50721C2 UA97052122A UA97052122A UA50721C2 UA 50721 C2 UA50721 C2 UA 50721C2 UA 97052122 A UA97052122 A UA 97052122A UA 97052122 A UA97052122 A UA 97052122A UA 50721 C2 UA50721 C2 UA 50721C2
Authority
UA
Ukraine
Prior art keywords
cisapride
tartrate
release formulation
extended release
dosage forms
Prior art date
Application number
UA97052122A
Other languages
English (en)
Russian (ru)
Inventor
Ежен Марі Жозеф Жанс
Поль Марі Віктор Гіліс
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA50721C2 publication Critical patent/UA50721C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується лікарських форм уповільненого вивільнення, які містять цизаприд-L-тартрат, суміш гідроксипропілметилцелюлози та іншого в’язкого полімеру. Лікарські форми можуть вживатись перорально для лікування порушень кінетики шлунка.
UA97052122A 1994-11-02 1995-10-25 Композиція з подовженою дією, що містить цизаприд-(l)-тартрат UA50721C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203184 1994-11-02
PCT/EP1995/004198 WO1996014070A1 (en) 1994-11-02 1995-10-25 Cisapride extended release oral compositions

Publications (1)

Publication Number Publication Date
UA50721C2 true UA50721C2 (uk) 2002-11-15

Family

ID=8217338

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97052122A UA50721C2 (uk) 1994-11-02 1995-10-25 Композиція з подовженою дією, що містить цизаприд-(l)-тартрат

Country Status (29)

Country Link
US (2) US6153623A (uk)
EP (1) EP0789572A1 (uk)
JP (1) JP3182423B2 (uk)
KR (1) KR100255521B1 (uk)
AP (1) AP658A (uk)
AR (1) AR001765A1 (uk)
AU (1) AU704284B2 (uk)
BG (1) BG63244B1 (uk)
BR (1) BR9509565A (uk)
CA (1) CA2203663C (uk)
CZ (1) CZ287844B6 (uk)
EE (1) EE03510B1 (uk)
FI (1) FI971856L (uk)
HR (1) HRP950539A2 (uk)
HU (1) HUT77887A (uk)
IL (1) IL115843A0 (uk)
MY (1) MY113092A (uk)
NO (1) NO312538B1 (uk)
NZ (1) NZ295166A (uk)
OA (1) OA10419A (uk)
PL (1) PL181470B1 (uk)
RO (1) RO116042B1 (uk)
RU (1) RU2143890C1 (uk)
SK (1) SK54297A3 (uk)
TR (1) TR199501351A2 (uk)
TW (1) TW466114B (uk)
UA (1) UA50721C2 (uk)
WO (1) WO1996014070A1 (uk)
ZA (1) ZA959221B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
US6126970A (en) * 1995-12-01 2000-10-03 Janssen Pharmaceutica N.V. Cisapride sustained release
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
CA2275604A1 (en) * 1997-01-03 1998-07-09 Kenneth Iain Cumming Sustained release cisapride mini-tablet formulation
AU7919398A (en) * 1997-06-11 1998-12-30 Janssen Pharmaceutica N.V. Immediate release ph-independent solid dosage form of (+)- or (-)-cisapride
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
EP1060743A1 (en) * 1999-06-17 2000-12-20 Development Center For Biotechnology Oral cisapride dosage forms with an extended duration
PT1218889E (pt) * 1999-09-28 2010-03-08 Panacea Biotec Ltd Composições de libertação controlada compreendendo nimesulida
AU2002223572B2 (en) 2000-09-29 2005-09-08 Abbvie B.V. Ion-strength independent sustained release pharmaceutical formulation
ES2312525T3 (es) * 2002-05-21 2009-03-01 Watson Laboratories, Inc. Formulacion farmaceutica con liberacion prolongada.
US8617596B2 (en) 2006-04-12 2013-12-31 Nippon Soda Co., Ltd. Sustained-release tablet production process
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
ATE173159T1 (de) * 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
WO1994001112A1 (en) * 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
BG63244B1 (bg) 2001-07-31
AU3844795A (en) 1996-05-31
AP9700969A0 (en) 1997-04-30
FI971856A7 (fi) 1997-04-30
EE9700105A (et) 1997-12-15
IL115843A0 (en) 1996-01-31
HUT77887A (hu) 1998-09-28
US6274599B1 (en) 2001-08-14
TR199501351A2 (tr) 1996-06-21
CA2203663A1 (en) 1996-05-17
RU2143890C1 (ru) 2000-01-10
MX9703249A (es) 1997-07-31
MY113092A (en) 2001-11-30
JPH09511760A (ja) 1997-11-25
ZA959221B (en) 1997-04-30
AU704284B2 (en) 1999-04-15
TW466114B (en) 2001-12-01
FI971856A0 (fi) 1997-04-30
WO1996014070A1 (en) 1996-05-17
PL181470B1 (pl) 2001-07-31
BR9509565A (pt) 1997-09-16
FI971856L (fi) 1997-04-30
KR100255521B1 (ko) 2000-05-01
HRP950539A2 (en) 1997-08-31
NZ295166A (en) 1999-03-29
SK54297A3 (en) 1997-10-08
NO971832D0 (no) 1997-04-21
BG101401A (bg) 1997-12-30
US6153623A (en) 2000-11-28
RO116042B1 (ro) 2000-10-30
AR001765A1 (es) 1997-12-10
PL319948A1 (en) 1997-09-01
CZ124497A3 (en) 1997-08-13
NO971832L (no) 1997-04-21
EE03510B1 (et) 2001-10-15
EP0789572A1 (en) 1997-08-20
JP3182423B2 (ja) 2001-07-03
OA10419A (en) 2001-12-06
NO312538B1 (no) 2002-05-27
CZ287844B6 (en) 2001-02-14
AP658A (en) 1998-08-17
CA2203663C (en) 2002-04-30

Similar Documents

Publication Publication Date Title
UA50721C2 (uk) Композиція з подовженою дією, що містить цизаприд-(l)-тартрат
EA200000718A1 (ru) Композиции целекоксиба
DK0845989T3 (da) Smertelindrende lægemiddelsammensætning
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
GEP20074244B (en) Compounds that modulate ppar activity and methods for their preparation
EA200401009A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
DE69812159D1 (de) Derivate des adamantan
PT1041987E (pt) Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP1566174A3 (en) Flash-melt oral dosage formulation
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
PT1061929E (pt) Composicao farmaceutica a base de progesterona natural de sintese e de estradiol e processo para a sua preparacao
ATE291914T1 (de) Zolmitriptanhaltige arzneizusammensetzungen
DK0770384T3 (da) Faste, vandfrie farmaceutiske sammensætninger til vaginal anvendelse
BR9809571A (pt) Composição medicinal e processo para produzì-la
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
BG104357A (en) Derivatives of cyclopentene used as motiline receptor antagonists
ATE360428T1 (de) Analgetisches arzneimittel
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
HUP9902135A2 (hu) (+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására